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Abstract
Although scientific literature has demonstrated the relevance of oral hygiene with chlorhexidine in preventing ventilation-
-associated pneumonia, there is a wide variation of concentrations, frequency and techniques when using the antiseptic. 
The aim of this research was to assess the best chlorhexidine concentration used to perform oral hygiene to prevent ven-
tilation-associated pneumonia. A systematic review followed by four meta-analysis using chlorhexidine concentration as 
criterion was carried out. Articles in English, Spanish or Portuguese indexed in the Cochrane, Embase, Lilacs, PubMed/Me-
dline and Ovid electronic databases were selected. The research was carried out from May to June 2011. The primary ou-
tcome measure of interest was ventilation-associated pneumonia. Ten primary studies were divided in four groups (G1-4), 
based on chlorhexidine concentration criterion. G1 (5 primary studies, chlorhexidine 0.12%) showed homogeneity among 
studies and the use of chlorhexidine represented a protective factor. G2 (3 primary studies, chlorhexidine 0.20%) showed 
heterogeneity among studies and chlorhexidine did not represent a protective factor. G3 (2 primary studies, chlorhexidine 
2,00%) showed homogeneity among studies and the use of chlorhexidine was significant. G4 (10 primary studies with 
different chlorhexidine concentrations) showed homogeneity among studies and the common Relative Risk was signifi-
cant. Statistic analyses showed a protective effect of oral hygiene with chlorhexidine in preventing ventilation-associated 
pneumonia. However, it was not possible to identify a standard to establish optimal chlorhexidine concentration.
Keywords: Oral Hygiene. Chlorhexidine. Pneumonia. Infection Control. Nursing.
Resumo
Embora a literatura científica tenha demonstrado a importância da higiene bucal com clorexidina na prevenção de pneu-
monia associada à ventilação, existe uma grande variação das concentrações, frequência e técnica de aplicação do an-
tisséptico. O objetivo desta pesquisa foi avaliar a melhor concentração de clorexidina usada para realizar a higiene bucal 
na prevenção de pneumonia associada à ventilação mecânica. Foi realizada uma revisão sistemática seguida de quatro 
meta-análises usando como critério a concentração de clorexidina. Foram selecionados artigos em Inglês, Espanhol ou 
Português indexados nas bases de dados eletrônicas: Cochrane, Embase, Lilacs, PubMed / Medline e Ovid. A pesquisa foi 
realizada no período de maio a junho de 2011. O desfecho primário de interesse foi a pneumonia associada à ventilação 
mecânica. Dez estudos primários foram divididos em 4 grupos (G1-4), com base no critério de concentração de clorexidi-
na. G1 (5 estudos primários, clorexidina 0,12%) apresentaram homogeneidade e o uso de clorexidina demonstrou efeito 
protetor; G2 (3 estudos primários, clorexidina 0,20%) houve heterogeneidade entre os estudos e clorexidina não represen-
tou um fator de proteção; G3 (2 estudos primários, clorexidina 2,00%) homogeneidade entre os estudos e a utilização de 
clorexidina foi significativa; G4 (10 estudos preliminares com diferentes concentrações de clorexidina) homogeneidade 
entre os estudos e o Risco Relativo comum foi significativo. A análise estatística mostrou um efeito protetor da higiene bu-
cal com clorexidina na prevenção de pneumonia associada à ventilação mecânica. No entanto, não foi possível identificar 
um padrão para estabelecer a concentração ideal de clorexidina para realização de higiene bucal.
Palavras-chave: Higiene Bucal. Clorexidina. Pneumonia. Controle de Infecções. Enfermagem.
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INTRODUCTION
The association between the oral cavity 
microbiota and pneumonia is well known, es-
pecially in critically-ill patients1. However, the 
acknowledgement of oral hygiene as a direct 
and relevant measure in preventing pneumonia 
in critically-ill patients is recent. Current guide-
lines for prevention of respiratory infections from 
the Center for Disease Control and Prevention of 
United States of America have recommended the 
implementation of a program that includes oral 
hygiene for these patients2.
The colonization of the oropharynx, nasal 
cavity and teeth of critically-ill patients can change 
due to metabolic decompensations such as 
acidosis, uremia, uncontrolled diabetes mellitus, 
hypotension, and the use of antibiotics3. The oral 
cavity may also suffer invasion from exogenous 
microorganisms through the use of respiratory 
equipment and contact with healthcare workers4. 
It is known that microorganisms from the oral 
cavity can be present in more than 60% of both 
the respiratory secretions from ventilated-assisted 
patients and in respiratory equipment used by 
them5.
Although the scientific literature has dem-
onstrated the relevance of oral hygiene to pre-
vent ventilator-associated pneumonia (VAP), 
there is no consensus on the use of chlorhex-
idine (CHX) as well as protocols to guide the 
indication, concentration, frequency, and tech-
nique used6.
In a systematic review published in 20077, 
the authors concluded that it would not pos-
sible to carry out a meta-analysis due to varia-
tions in methods and interventions found in the 
primary studies. Similarly, an integrative review 
concluded that it is necessary to perform further 
studies to determine the best way to perform oral 
hygiene8. Trials that assessed oral hygiene with 
CHX in VAP prevention have several variations 
regarding the intervention, such as the concentra-
tion of the antiseptic agent, frequency of product 
use, CHX presentation (gel, solution or spray) and 
way of applying the product (swab, sterile gauze 
or not sterile gauze). Systematic reviews and me-
ta-analyses have shown conflicting results on the 
importance of performing oral hygiene with CHX 
to prevent VAP9,10,11,12. In order to identify what is 
the best concentration of CHX to oral hygiene, 
we decided to perform a different meta-analysis, 
having as criterion the concentration of the anti-
septic agent.
The aim of this systematic review and me-
ta-analysis was to identify evidence on the best 
way to perform oral hygiene in ventilator-assisted 
critically-ill patients by means of a systematic re-
view and meta-analysis using CHX concentration 
as the criterion.
METHOD
A systematic review and meta-analysis was 
performed based on the steps recommended 
in the online course of Systematic Review and 
Meta-analysis of the Cochrane Center of Brazil13 
seeking to answer the following question: is there 
evidence on the best way to perform oral hygiene 
with CHX to prevent VAP in critically-ill patients? 
Study selection was performed by two indepen-
dent professionals that used the same search strat-
egy to the ensure accuracy.
The Preferred Reporting Items for System-
atic Reviews and Meta-analyses – PRISMA State-
ment14 – 27-item checklist was followed during 
article selection and study performance.
Search methods
Descriptors indexed in databases were used 
according to PICO strategy15, where P (Popula-
tion) = Respiration, Artificial OR Artificial Ven-
tilation OR Critical Care OR Critical illness OR 
Intensive care OR Intensive care nursing OR In-
tensive care units; I (Intervention) = Oral hygiene 
OR Mouth hygiene OR Mouthwashes; C (Com-
parison) = there was no descriptor to compare; O 
(Outcome) = Ventilation-associated pneumonia 
OR Cross infection OR Infection control.
The search was carried out from May to 
June 2011 in the following electronic databases: 
Cochrane Library, EMBASE, PubMed/MEDLINE, 
OVID and LILACS. The search included articles 
published in English, Spanish, and Portuguese 
with no time period limitation. References cited 
in included studies were also analyzed in order 
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to identify other relevant studies that were not lo-
cated by means of electronic search. 
Population was defined as critically-ill pa-
tients aged 18 years or older, undergoing mechan-
ical-assisted ventilation. Controlled randomized 
trials were included whenever they compared 
oral hygiene using CHX with placebo or usual 
care. Exclusion criteria were publications con-
cerning letters to editor, duplicated studies, com-
ments and opinions of experts that were not sup-
ported by research.
Search outcome
Initially, 205 publications were identified. 
After screening of titles, abstracts and reading of 
full-texts, 10 articles were selected for inclusion 
in the study. Seven studies that were reviews or 
meta-analyses were not included in the final sam-
ple of 10 studies (Figure 1), but had their literature 
references analyzed6,7,8,9,10,11,12.
Figure 1. Flow diagram of studies selection 
process
Quality appraisal
The quality of studies was assessed according 
to the Oxford classification16, Jadad score17 and in-
ternal and external validity18. The first classifies the 
studies according to levels of evidence and select-
ed only clinical trials. The second establishes the 
maximum value of five points, as follows: random-
ized (1 point), adequate randomization process (1 
point), blinding (1 point), double-blind (1 point), 
and control of subject loss or exclusions (1 point). 
The studies included in this review have a clas-
sification > 3 according to Jadad score17. The third 
evaluates aspects related to control of confound-
ing variables, stratification of the intervention and 
control groups and population. Two authors inde-
pendently assessed the three criteria cited in all 
studies of this review in order to ensure that the 
included studies represented strong evidence.
Data abstraction
Data were extracted by one author using a 
instrument designed specifically to obtain the fol-
lowing details: age, sex, intervention details, and 
control groups, concentration of antiseptic agent, 
frequency of use of antiseptic agent and way of 
performing the oral hygiene. The main outcome 
evaluated by the studies was the development of 
ventilation-associated pneumonia. 
Synthesis
The selected primary studies were grouped 
into 4 groups (G1 to G4). The groups were consti-
tuted as follows: G1 – five trials that used 0.12% 
CHX; G2 – three trials that used 0.20% CHX; G3 
– two trials that used 2.00% CHX; G4 – comprised 
all 10 studies that evaluated the use of CHX in re-
ducing VAP. The statistical methodology of the 98c 
EasyMA® package was applied to each group and 
a fixed-effects model was used to synthesize data 
Cochran’s Q test was used to evaluate the homo-
geneity among studies.
RESULTS
Description of trials
The 10 clinical trials enrolled 2,471 patients: 
1,237 receiving  oral hygiene with CHX and 1,234 
that constituted the control group (Table 1). Sub-
jects from the control groups received placebo 
(483), usual care (35), electric toothbrush (73), 
mouthwash containing phenolic compounds - Lis-
terine (291) or saline solution (352).
As shown in Table 1, studies with 0.12% CHX 
used liquid solution presentation; studies with 
0.20% CHX used gel; and trials with 2.00% CHX 
used gel or solution.
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Studies E2, E5, E7, E8 excluded edentulous 
patients and the last one also excluded patients 
with a tracheostomy tube. E2 justified that eden-
tulous patients may have other potential patho-
gens and therefore a different risk level for VAP 
compared to patients with teeth. Nevertheless, 
this particular patient characteristic was not even 
mentioned in studies E1, E3, E6, E9, E10 and 
study E4 included edentulous subjects.
E8 is a multicenter study that took place in 
six French ICUs: three in university hospitals and 
three in general hospitals. E9 was multicenter 
and was performed in two university hospitals 
(two mixed and two surgical ICUs) and three 
general hospitals (all mixed ICUs) in the Neth-
erlands. E10 was a singular study, as the authors 
carried out a randomized clinical trial with 207 
patients in ICUs or general medical wards from a 
tertiary care university hospital (102 individuals 
in the Intervention group and 105 in the control 
group) and then performed a meta-analysis with 
a single study that also used 2.00% CHX (E9, in 
the present study). E10 used the patients’ gender 
as a criterion for group composition. This means 
that intervention group was consisted of male 
patients and the control group of female patients.
Regarding the technique used, studies E5 
and E9 did not refer whether the gauze or glove, 
respectively, which were used to apply CHX 
were sterile or not. In the E8 study, before CHX 
use, mouth-rinsing with water and oropharyn-
geal aspiration was performed. Tooth brushing 
was not allowed in the protocol of this study, 
aiming at eliminating bias regarding the CHX 
effect. E9 reports that before each intervention 
cleaning with gauze moistened with saline solu-
tion (NaCl 0.9%) was performed and E10 indi-
cates that before patients received CHX or saline 
solution, teeth were brushed and oral secretions 
were aspirated.
Study
Intervention 
group (I)
Control group 
(C) Freq/
day
CHX presentation 
Application Quantity Contact time
Type of 
patient 
(Intensive care 
unit)
Blinding ↓VAP
NI
VAPI
Yes
NC
VAPC 
Yes
Interven-
tion
Control
CHX 0.12%
E119 (DeRiso, et 
al., 1996)
173 9 180 9 2x solution
placebo 
solution
not cited 5 fl oz
30s
Cardiovascular
double-
-blind
Yes
E220 (Grap, et al., 
2004)
7 4 5 3 2x solution usual care
spray or 
swab
2mL Not cited
trauma and 
surgical
triple-blind
CHX use early in 
the post-intubation 
period may delay the
development of VAP
E321 (Houston, et 
al., 2002)
270 4 291 9 2x solution Listerine® swab 15mL
30s. No food 
or drink for 30 
min after
cardiovascular not cited
only in intubated 
patients > 24h
E422 (Scannapie-
co, et al., 2009)
116 14 59 12 2x solution
placebo 
solution
swab 1 fl oz 1 min trauma
double-
-blind
No
E523 (Pobo, et al., 
2009)
74 15 73 18 3x solution
electric 
toothbrush
gauze
20mL 
rub-
bing + 
injection 
10mL
30s
medical-
surgical
single-blind No
CHX 0.20%
E624 (Panchabhai, 
et al., 2009)
224 16 247 19 2x solution
0.01% 
KmnO4 
solution
swab 10mL
Not cited. No 
food or drink 
for 1h after
general not cited No
E725 (Fourrier, et 
al., 2000)
30 5 30 18 3x gel usual care sterile glove Not cited
Gel was left 
until next time
medical-
-surgical
single-blind Yes
E826 (Fourrier, et 
al., 2005)
114 13 114 12 3x gel placebo gel sterile glove Not cited
Gel was left 
until next time
6 ICUs (multi-
center)
double-
-blind
No
CHX 2.00%
E927 (Koeman, et 
al., 2006)
127 13 130 23 4x
vaseline 
FNA / 
colistin in 
vaseline 
FNA
placebo 
(vaseline 
FNA)
glove 0.5g
Product was 
left until next 
time
mixed & 
surgical
double-
-blind
Yes
E1028 (Tantipong, 
et al., 2008)
102 5 105 12 4x solution
saline solu-
tion
Not cited 15 mL
15 mL. Time 
not cited.
ICUs or gen-
eral medical 
wards
Yes
Table 1. Number of subjects in the intervention (I) or control (C) group, frequency of use, chlorhexidine (CHX) 
presentation, type of use, volume, contact time, patients characteristics, blinding status, and outcome of Ven-
tilation-Associated Pneumonia (VAP) reduction in 10 selected studies. Brazil, 2012
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E1 used a placebo that was similar to the base 
solution of CHX; this means that both interven-
tion and placebo group had 3.2% ethyl alcohol as 
solvent. On the other hand, study E4 used a lower 
concentration of ethanol in the placebo (< 0.1%).
In the E7 study, usual care was defined 
and applied in the control group by means of a 
bicarbonate serum followed by oropharyngeal 
sterile aspiration four times a day.
Meta-analysis 
Four meta-analyses were carried out ac-
cording to CHX concentration groups as previ-
ously defined. Group 1 (G1) included studies 
that used 0.12% CHX; Group 2 (G2) studies 
with 0.20% CHX; Group 3 (G3) 2.00% CHX 
and Group 4 (G4) did not include the criterion 
of CHX concentration.
The meta-analysis of G1 (Figure 2) showed 
that the studies were homogeneous (Q Cochrane 
heterogeneity p = 0.67). We verified the occur-
rence of large confidence intervals in the studies, 
of which all crossed the line at 1.0 and can be 
seen as the possibility of no beneficial effect or 
a negative effect. However, after grouping these 
studies, oral hygiene with 0.12% CHX represent-
ed a protective factor (RR = 0.675; p = 0.039). 
In the meta-analysis of G2 (Figure 3) there 
was heterogeneity among studies (Q Cochrane 
heterogeneity p = 0.037), indicating that this 
meta-analysis does not have good statistical 
power. It should be pointed out that only E7 did 
not cross the line at 1.0, so CHX represented a 
protective factor only in this study.
The meta-analysis of G3 (Figure 4) showed 
homogeneity among studies (Cochrane Q het-
erogeneity p = 0.62), which also had large con-
fidence intervals and both studies E9 and E10 
touch the line 1.0. This meta-analysis showed 
that the use of CHX was significant (p = 0.021) 
for the prevention of VAP and the RR = 0.53.
Finally, the meta-analysis of all 10 primary 
studies (Figure 5) showed homogeneity among the 
groups (Cochrane Q heterogeneity p = 0.35). The 
confidence interval did not cross the line at 1.0 
and the Relative Risk was lower for patients using 
CHX (RR = 0.658; p < 0.001).
Figure 2. Meta-analysis of studies that used CHX 
0.12% (Group 2) in oral hygiene to reduce the 
incidence of VAP. Brazil, 2012
Figure 3. Meta-analysis of studies that used 
0.20% CHX (Group 3) in oral hygiene to reduce 
the incidence of VAP. Brazil, 2012
Figure 4. Meta-analysis of studies that used CHX 
2.00% (Group 4) in oral hygiene to reduce the inci-
dence of VAP. Brazil, 2012
Figure 5. Meta-analysis of studies that used CHX in oral 
hygiene to reduce the incidence of VAP. Brazil, 2012
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DISCUSSION
Systematic reviews and meta-analyses should 
be performed when there are doubts about the suf-
ficiency of conclusions found by well-designed clin-
ical trials or when new issues arise. Regarding the 
subject under investigation, although previous stud-
ies suggested that the use of oral hygiene with CHX 
prevents VAP, the best antiseptic concentration and 
the best way to do it remains an open question. 
We chose to perform four different meta-analy-
ses, having as the criterion for inclusion of studies the 
concentration of CHX. We believed that by assessing 
studies in similar categories we could evaluate the 
best concentration to perform oral hygiene.
Many studies showed large confidence in-
tervals. Despite of a trend to use CHX to prevent 
VAP, only a single study (E7) had not crossed the 
line at 1.0, showing that the use of this antiseptic 
was effective in this study. 
In the meta-analysis of G1 studies (CXH con-
centration of 0.12%) CHX was not identified as 
being protective, maybe due to the low antiseptic 
concentration. Meta-analysis of G2 studies (0.20% 
CHX concentration) was considered inconclusive. 
VAP protection was identified in the meta-analysis 
of G3 (2.00% concentration). However, is a matter 
of discussion whether the gender criterion used in 
the E10 study could introduced a bias in the ran-
domization28.
The hypothesis of performing different meta-
analyses using the concentration of the antiseptic 
agent as inclusion criterion to help establish the best 
way to perform oral hygiene unfortunately did not 
yield with significant results.
On the other hand, although the meta-analy-
sis with all studies included in the review showed 
that there is was a protective effect of CHX use in 
oral hygiene, it was impossible to determine which 
CHX concentration is the best one. However, it is 
important to highlight that the meta-analysis re-
sults can be affected by other important variables 
in addition to CHX concentration, such as the form 
of presentation (solution, gel, spray), frequency 
and methods used (swab, gauzes or gloves). The 
best way to determine a standard recommenda-
tion would be to compare researches that followed 
similar interventions, including the antiseptic form 
and the frequency of use.
Moreover, it is important to note that CHX is 
not innocuous. In case of oral ingestion, although the 
product is well tolerated in most cases, adverse ef-
fects may occur when ingested in large quantities29. 
Cases of pulmonary and tongue edema and oral ul-
cers in infants who received 0.05% CHX orally after 
the antiseptic agent was mistaken for sterile water 
have been reported30. After developing respiratory 
distress syndrome, an elderly patient died due to in-
gestion of 10 g of CHX in a 200 mL solution31. When 
performing oral hygiene with CHX, one should be 
careful not to allow contact with the eyes. Tests with 
4% CHX caused stromal edema in animals, leading 
to corneal opacification within six weeks32. CHX is 
also toxic to the middle ear. Disinfection of the ear 
with CHX during preoperative procedures has been 
associated with deafness after myringoplasty33. 
Among fifty cases of adverse reactions related 
to CHX that occurred in Japan from 1967 to 1984, 
nine cases of anaphylaxis shock were reported, par-
ticularly when CHX was applied to the mucosa34. 
A similar case was described in Australia after CHX 
was applied to the vaginal mucosa at the end of a 
surgery35.
Thus, even though we conclude that CHX is a 
product that can reduce the microbiota of the oral 
cavity or VAP, guidelines for its best use, which are 
less likely to cause harmful effects are essential in re-
lation to cost-benefit to the patient. Nursing plan in 
critically-ill patients regarding oral care should be 
evidence-based and the use of chlorhexidine must be 
judicious, besides is important that nurses having suf-
ficient time to provide care, prioritizing oral care36.
CONCLUSION
When evaluating studies on the protective ef-
fect of CHX use in VAP prevention, it was not pos-
sible to establish a consensus regarding a standard 
recommendation about the antiseptic concentra-
tion to be used.
Well-designed primary studies, including 
careful control of confounding variables between 
the groups are still needed in order to identify the 
best concentration, frequency, technique and form 
of presentation of CHX. In addition, studies to ver-
ify the potential toxicity of CHX in contact with 
mucosal membranes should also be developed to 
ensure patient safety.
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